XINTELA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3 SEK | +0.67% |
|
+1.35% | +10.70% |
| 05-24 | Xintela AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 05-23 | Xintela and EQGen Biomedical to Collaborate to Develop EQSTEM Stem Cell Treatment for Horses | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 16.05M | - | - | - | - | - | |
| 39.36B | ||||||
| 38.52B | ||||||
| 30.74B | - | |||||
| 25.92B | ||||||
| 26.03B |
- Stock Market
- Equities
- XINT Stock
- Charts Xintela AB
- Sector Chart
